Head-to-head evidence
Fluticasone propionate/salmeterol (Advair HFA) vs GW642444M
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00158834 · Phase 3 · completed
The study randomized 200 children and used double blinding with an active fluticasone comparator. Its primary endpoint was the clinical measure of asthma symptom-free days, but no results are posted, so whether that endpoint was met cannot be determined.
GW642444M
Developed by GlaxoSmithKline
NCT00600171 · Phase 2 · completed
The study was randomized and double-blind, compared five GW642444M doses with placebo, and included 614 randomized participants. Its primary lung-function endpoint was a surrogate measure rather than a direct clinical outcome, and the results were mixed across doses: the 12.5, 25, and 50 microgram doses outperformed placebo, while the 3 and 6.25 microgram doses did not.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair HFA)'s landscape · GW642444M's landscape